BR0114835A - Therapeutic compositions for treatment of lawsonia spp infection - Google Patents
Therapeutic compositions for treatment of lawsonia spp infectionInfo
- Publication number
- BR0114835A BR0114835A BR0114835-4A BR0114835A BR0114835A BR 0114835 A BR0114835 A BR 0114835A BR 0114835 A BR0114835 A BR 0114835A BR 0114835 A BR0114835 A BR 0114835A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- therapeutic compositions
- lawsonia intracellularis
- present
- lawsonia
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 241001469654 Lawsonia <weevil> Species 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 241001148567 Lawsonia intracellularis Species 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 241001465754 Metazoa Species 0.000 abstract 2
- 208000028774 intestinal disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 244000005700 microbiome Species 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 241001239379 Calophysus macropterus Species 0.000 abstract 1
- 101100424487 Escherichia coli (strain K12) tamA gene Proteins 0.000 abstract 1
- 101100424491 Escherichia coli (strain K12) tamB gene Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 101150068991 flhB gene Proteins 0.000 abstract 1
- 101150026424 fliR gene Proteins 0.000 abstract 1
- 101150065098 glnG gene Proteins 0.000 abstract 1
- -1 glnH Proteins 0.000 abstract 1
- 230000004727 humoral immunity Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 101150052329 motA gene Proteins 0.000 abstract 1
- 101150110871 motB gene Proteins 0.000 abstract 1
- 101150012415 ntrC gene Proteins 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 101150092975 tlyC gene Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
"COMPOSIçõES TERAPêUTICAS PARA TRATAMENTO DE INFECçãO POR LAWSONIA SPP". A presente invenção refere-se geralmente a composições terapêuticas para o tratamento e/ou profilaxia de condições de doença intestinal em animais e pássaros causadas ou exacerbadas pelo Lawsonia intracellularis ou microorganismo similar ou de outro modo relacionado. Em particular, a presente invenção fornece um novo gene derivado de Lawsonia intracellularis, que codifica um polipeptídeo imunogênico que é particularmente útil como um antígeno em uma prepração de vacina para conferir imunidade humoral contra o Lawsonia intracellularis e patógenos relacionados em hospedeiros animais, onde o referido polipeptídeo é selecionado do grupo consistindo em polipeptídeos flhB, fliR, ntrC, glnH, motA, motB, tlyC, ytfM e ytfN, ou um homólogo, análogo ou derivado de qualquer um ou mais dos referidos polipeptídeos. A presente invenção é também direcionada a métodos para o tratamento e/ou a profilaxia de tais condições de doença intestinal e a agentes diasgnósticos e procedimentos para detectar o Lawsonia intracellularis ou microorganismos similares ou de outro modo relacionados."THERAPEUTIC COMPOSITIONS FOR LAWSONIA SPP INFECTION TREATMENT". The present invention generally relates to therapeutic compositions for the treatment and / or prophylaxis of intestinal disease conditions in animals and birds caused or exacerbated by Lawsonia intracellularis or similar or otherwise related microorganism. In particular, the present invention provides a novel Lawsonia intracellularis-derived gene, which encodes an immunogenic polypeptide that is particularly useful as an antigen in a vaccine preparation for conferring humoral immunity against Lawsonia intracellularis and related pathogens in animal hosts, where said A polypeptide is selected from the group consisting of flhB, fliR, ntrC, glnH, motA, motB, tlyC, ytfM and ytfN polypeptides, or a homologue, analog or derivative of any one or more of said polypeptides. The present invention is also directed to methods for the treatment and / or prophylaxis of such intestinal disease conditions and to diagnostic agents and procedures for detecting Lawsonia intracellularis or similar or otherwise related microorganisms.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPR1381A AUPR138100A0 (en) | 2000-11-10 | 2000-11-10 | Novel therapeutic compositions for treating infection by lawsonia spp |
US24959600P | 2000-11-17 | 2000-11-17 | |
PCT/AU2001/001462 WO2002038594A1 (en) | 2000-11-10 | 2001-11-09 | Novel therapeutic compositions for treating infection by lawsonia spp |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0114835A true BR0114835A (en) | 2003-07-01 |
Family
ID=25646507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0114835-4A BR0114835A (en) | 2000-11-10 | 2001-11-09 | Therapeutic compositions for treatment of lawsonia spp infection |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1332154A4 (en) |
JP (1) | JP2004512851A (en) |
BR (1) | BR0114835A (en) |
CA (1) | CA2399276A1 (en) |
MX (1) | MXPA03003077A (en) |
NZ (1) | NZ520600A (en) |
WO (1) | WO2002038594A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1570045A4 (en) * | 2002-10-04 | 2007-09-05 | Univ Minnesota | Nucleic acid and polypeptide sequences from lawsonia intracellularis and methods of using |
US8834891B2 (en) | 2005-03-14 | 2014-09-16 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
US8398994B2 (en) | 2005-07-15 | 2013-03-19 | Boehringer Ingelheim Vetmedica, Inc. | Lawsonia vaccine and methods of use thereof |
EP2101815A4 (en) | 2006-12-11 | 2010-10-06 | Boehringer Ingelheim Vetmed | Effective method of treatment of porcine circovirus and lawsonia intracellularis infections |
FR2980213B1 (en) * | 2011-09-16 | 2013-09-06 | Biomerieux Sa | PROCESS FOR CHARACTERIZING BACTERIA BY DETECTION OF NON-STRUCTURAL PROTEINS OF BACTERIOPHAGES |
US9359643B2 (en) | 2013-03-08 | 2016-06-07 | Progenika Biopharma S.A. | Discrimination of blood type variants |
CL2017002196A1 (en) | 2017-08-30 | 2017-11-17 | Univ De Concepción | Recombinant vaccine against proliferative enteropathy in animals. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5885823A (en) * | 1995-06-05 | 1999-03-23 | Nobl Laboratories, Inc. | Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents |
WO1997020050A1 (en) * | 1995-11-30 | 1997-06-05 | Daratech Pty. Ltd. | Therapeutic and diagnostic compositions |
US6627728B1 (en) * | 1998-05-12 | 2003-09-30 | Smithkline Beecham Biologicals S.A. | Compounds from moraxella catarrhalis |
TWI224107B (en) * | 1998-10-22 | 2004-11-21 | Pfizer Prod Inc | Novel proteins from actinobacillus pleuropneumoniae |
GB9902880D0 (en) * | 1999-02-09 | 1999-03-31 | Smithkline Beecham Biolog | Novel compounds |
-
2001
- 2001-11-09 BR BR0114835-4A patent/BR0114835A/en not_active IP Right Cessation
- 2001-11-09 MX MXPA03003077A patent/MXPA03003077A/en unknown
- 2001-11-09 JP JP2002541925A patent/JP2004512851A/en active Pending
- 2001-11-09 CA CA002399276A patent/CA2399276A1/en not_active Abandoned
- 2001-11-09 EP EP01983297A patent/EP1332154A4/en not_active Withdrawn
- 2001-11-09 WO PCT/AU2001/001462 patent/WO2002038594A1/en not_active Application Discontinuation
- 2001-11-09 NZ NZ520600A patent/NZ520600A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2002038594A1 (en) | 2002-05-16 |
MXPA03003077A (en) | 2003-09-25 |
JP2004512851A (en) | 2004-04-30 |
CA2399276A1 (en) | 2002-05-16 |
EP1332154A1 (en) | 2003-08-06 |
EP1332154A4 (en) | 2005-05-11 |
WO2002038594A9 (en) | 2002-11-07 |
NZ520600A (en) | 2004-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cawthraw et al. | Increased colonization potential of Campylobacter jejuni strain 81116 after passage through chickens and its implication on the rate of transmission within flocks | |
NO20111324A1 (en) | Recombinant MVA virus | |
ATE329031T1 (en) | THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF LAWSONIA INTRACELLULARIS INFECTIONS | |
US10704027B2 (en) | Bacteriophage and antibacterial composition comprising the same | |
WO2014133290A1 (en) | Novel bacteriophage and antibacterial composition comprising the same | |
WO2014133323A1 (en) | Novel bacteriophage and antibacterial composition comprising the same | |
DE60316772D1 (en) | DIABETIC AND / OR PHARMACEUTICAL PREPARATIONS USED BY HUMANS OR ANIMALS, BASED ON PROBIOTIC MICROORGANISMS | |
DK1185660T3 (en) | Pig circovirus vaccine in recombinant pox virus | |
ATE366312T1 (en) | VACCINE AND ANTITOXINS FOR THE TREATMENT AND PREVENTION OF C. DIFFICILE DISEASES | |
EP1854886A3 (en) | Cold-adapted equine influenza viruses | |
WO2014133322A1 (en) | Novel bacteriophage and antibacterial composition comprising the same | |
WO2014133289A1 (en) | Novel bacteriophage and antibacterial composition comprising the same | |
BR9910749A (en) | Combined immunogenic compositions and vaccines for meningitis b and c and method of inducing an immune response by administering the same | |
BR0114835A (en) | Therapeutic compositions for treatment of lawsonia spp infection | |
MX2012003827A (en) | A cytolytic rtx-toxin from gallibacterium anatis. | |
BRPI0419273A (en) | compositions and methods for treating microbial and parasitic infections in cattle and other animals | |
BR0011292A (en) | Gene derived from lawsonia and related sodc proteins, peptides and polypeptides and their uses | |
NZ515330A (en) | Lawsonia derived gene and related OmpH polypeptides, peptides and proteins and their uses | |
US20190015495A1 (en) | Vaccine strains of brachyspira hyodysenteriae | |
BR0011294A (en) | Gene derived from lawsonia and related polypeptides, peptides and proteins and their uses | |
HUP9700975A2 (en) | Live attenuated rtx-producing bacteria of the family pasteurellaceae | |
Lentsch et al. | Combining oral vaccination and niche competition to fight antimicrobial resistance gene reservoirs | |
WO2023066229A3 (en) | Recombinant classical swine fever virus e2 protein with b/c domain swapping | |
Chattopadhayay | New born chicks can serve as an experimental animal model for human campylobacteriosis | |
Herman et al. | Study of the pathogenic factors produced by Actinobacillus pleuropneumoniae. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2021 DE 29/09/2009. |